Article Text

PDF
Orthovoltage radiation and weekly low dose of doxorubicin for the treatment of incompletely excised soft-tissue sarcomas in 39 dogs
  1. D. Simon, DrMedVet, DipECVIM-ca1,
  2. D. M. Ruslander, DVM, DACVR, DACVIM1,
  3. K. M. Rassnick, DVM, DACVIM1,
  4. C. A. Wood, DVM, DACVIM1,
  5. A. E. Frimberger, VMD, DACVIM1,
  6. S. M. Cotter, DVM, DACVIM1,
  7. N. W. King, DVM, DACVP2 and
  8. A. S. Moore, BVSc, MVSc, DACVIM1
  1. 1 Harrington Oncology Program, Tufts University School of Veterinary Medicine, North Grafton, MA 01536, USA
  2. 2 Department of Pathology, Tufts University School of Veterinary Medicine, North Grafton, MA 01536, USA
  1. Dr Simon's present address is Department of Small Animal Medicine and Surgery, University of Veterinary Medicine Hannover, Bischofsholer Damm 15, D-30173 Hannover, Germany

Abstract

The efficacy and toxicity of orthovoltage radiation therapy and concurrent low doses of doxorubicin for the treatment of incompletely excised soft-tissue sarcomas in 39 dogs was investigated retrospectively. The 39 dogs had 40 soft-tissue sarcomas and received 51 Gy orthovoltage radiation in 17 daily 3 Gy fractions; they also received 10 mg/m2 doxorubicin once a week administered intravenously one hour before the dose of radiation. The median follow-up time was 910 days. The tumours recurred locally in seven of the dogs, in five of them within the radiation field; the median time to their recurrence was 213 days (range 63 to 555 days). Six of the dogs developed a distant metastasis after a median time of 276 days (range eight to 826 days). The one-year and two- to four-year tumour control rates were 84 per cent and 81 per cent, respectively, and the one-, two- and three- to four-year survival rates were 85 per cent, 79 per cent and 72 per cent, respectively. Tumours with a mitotic rate of more than 9 per 10 high-power fields were significantly more likely to recur, and the dogs with such tumours survived for significantly shorter periods.

    Statistics from Altmetric.com

      Request permissions

      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.